抗坏血酸对糖尿病大鼠尿白蛋白及肾脏蛋白激酶C活性的影响
出处
《上海医学》
CAS
CSCD
北大核心
2004年第7期514-515,共2页
Shanghai Medical Journal
参考文献11
-
1Ha H, Kim KH. Pathogenesis of diabetic nephropathy: the role of oxidative stress and protein kinase C. Diabetes Res Clin Pract,1999,45:147-151.
-
2Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes,1998,47:859-866.
-
3West IC. Radicals and oxidative stress in diabetes. Diabet Med,2000,17:171-180.
-
4Evans JL, Goldfine ID, Maddux BA, et al. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev, 2002,23:599-622.
-
5Kashiba M, Oka J, Ichikawa R, et al. Impaired ascorbic acid metabolism in streptozotocin-induced diabetic rats. Free Radic Biol Med, 2002,33:1221-1230.
-
6Skrha J, Prazny M, Hilgertova J, et al. Serum alpha-tocopherol and ascorbic acid concentrations in Type 1 and Type 2 diabetic patients with and without angiopathy. Clin Chim Acta, 2003,329:103-108.
-
7Gaede P, Poulsen HE, Parving HH, et al. Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in Type 2 diabetic patients. Diabet Med,2001,18:756-760.
-
8Kowluru RA, Tang J, Kern TS. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. Ⅶ. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes, 2001,50:1938-1942.
-
9Kowluru RA, Engerman RL, Kern TS. Diabetes-induced metabolic abnormalities in myocardium: effect of antioxidant therapy. Free Radic Res, 2000,32:67-74.
-
10Konishi H, Yamauchi E, Taniguchi H, et al. Phospborylation sites of protein kinase C delta in H202-treated cells and its activation by tyrosine kinase in vitro. Proc Natl Acad Sci USA, 2001,98:6587-6592.
共引文献30
-
1苏青,冯绮文,董艳,邢惠莉,左静南.血管紧张素转化酶抑制剂和血管紧张素Ⅱ受体拮抗剂联合治疗对2型糖尿病患者尿白蛋白排泄的影响[J].上海医学,2005,28(1):16-19.
-
2徐东红,宋春青,李焕明,关薇.氯沙坦及依那普利对糖尿病肾病的治疗观察[J].中国心血管杂志,2006,11(3):182-184. 被引量:2
-
3吴玉鸿,黄燕南,肖树华.氯沙坦和辛伐他汀联合治疗早期糖尿病肾病的临床疗效[J].临床荟萃,2007,22(12):883-884. 被引量:2
-
4王希宁.通心络联合氯沙坦或培哚普利对糖尿病肾病的治疗观察[J].中国医师杂志,2007,9(10):1431-1432.
-
5朱巧红.洛汀新与代文联合治疗糖尿病肾病疗效观察[J].实用临床医药杂志,2007,11(5):95-96. 被引量:7
-
6赵静瑜,盛伟.缬沙坦、依那普利单用及联用对糖尿病肾病患者MAP、尿蛋白的影响[J].山东医药,2008,48(8):65-66. 被引量:3
-
7郑淑婷,韩峰,侯波.螺内酯联合缬沙坦治疗早期糖尿病肾病[J].临床肾脏病杂志,2008,8(4):174-175.
-
8向清,史伟,吴金玉,向彩春.贝那普利联合厄贝沙坦治疗糖尿病肾病疗效观察[J].中南药学,2008,6(4):490-493. 被引量:6
-
9林佃新,刘印,巩立营.前列腺素E1脂微球制剂联合厄贝沙坦治疗早期糖尿病肾病的疗效观察[J].安徽医药,2008,12(9):860-861. 被引量:12
-
10欧继红,杨放,万青松,谢红萍.小剂量缬沙坦治疗早期2型糖尿病肾病的临床研究[J].实用医学杂志,2009,25(9):1501-1502. 被引量:6
-
1赵同峰,邓华聪,赵江佩.阿魏酸钠对糖尿病大鼠肾脏蛋白激酶C活性的影响[J].浙江医学,2004,26(7):497-500. 被引量:2
-
2吕学爱,关广聚,文蓉珠,孙云,涂晓文.氨基胍对糖尿病大鼠肾脏保护作用的实验研究[J].山东大学学报(医学版),2006,44(6):597-601. 被引量:3
-
3王保兴,李英,吴文清,王秀芬,林海英,顾连方.氟伐他汀对糖尿病大鼠肾脏组织蛋白激酶C活性作用的影响[J].中国中西医结合肾病杂志,2005,6(3):140-142.
-
4王凌云,柳洁.吡格列酮对糖尿病大鼠肾脏组织蛋白激酶C活性的作用研究[J].山西医药杂志(上半月),2008,37(5):428-430.
-
5顾北令,陈峰,赵瑛.α-硫辛酸对糖尿病神经病变大鼠坐骨神经蛋白激酶C活性的影响[J].标记免疫分析与临床,2009,16(4):233-236.
-
6吴明昊,刘剑,胡桂才,高宇,吴晓静,周瑾,赵亚娟.利拉鲁肽对胰岛素抵抗大鼠肾脏蛋白激酶Cβ表达的影响[J].中华肾脏病杂志,2016,32(6):459-460.
-
7吕学爱,关广聚,孙云,涂晓文,文蓉珠,柳刚.氨基胍对糖尿病大鼠肾脏蛋白激酶C活性的调节及意义[J].中华肾脏病杂志,2004,20(5):371-372. 被引量:6
-
8叶娟,李果,陈家伦.高浓度胰岛素、葡萄糖对HepG2细胞蛋白激酶C活性的影响[J].中华内分泌代谢杂志,1999,15(5):294-297. 被引量:1
-
9李英,吴文清,张益民,李红.野黄芪甙原对糖尿病大鼠肾脏蛋白激酶C活性作用的研究[J].中华肾脏病杂志,2000,16(2):89-91. 被引量:108
-
10杨旭玲,葛华.血小板中蛋白激酶C活性在急性冠脉综合征患者体内的变化[J].中国实验诊断学,2006,10(6):611-612. 被引量:1